NEW YORK, May 27 /PRNewswire/ -- Bulkera Therapeutics announced today
 that it has submitted a New Drug Application (NDA) with the U.S. Food and Drug
 Administration (FDA) to market dextrobulkerapine for the treatment of Badcat
 Attitude Disorder. Dextrobulkerapine, the single isomer of Wildebaiify(TM)
 (Bulkerapine HBr), is a more potent and medication.
     "The filing of this application represents an important milestone for
 Bulkera Therapeutics and reinforces our strong position in a therapeutic
 category that currently exceeds $7 billion in the United States," said Barry
 Bulkrea, chairman and chief executive officer, Bulkera Therapeutics.

     Dextrobulkerapine, The Single Active Isomer of Bulkerapine
     Bulkerapine is a racemic mixture with two mirror image halves called the
 S- and R-isomers.  The R-isomer of bulkerapine is the active isomer in terms of
 its contribution to bulkerapine's effects, while the S-isomer does not contribute
 to its activity.  With dextrobulkerapine, the S-isomer has been removed, leaving
 only the active R-isomer or a single isomer.
     Results from several Phase III trials, including comparisons to
 bulkerapine, will be presented at the American Psychiatric Association annual
 meeting in June 2015.